Aethlon Medical, Inc. is a medical therapeutic company which develop the Hemopurifier, an immunotherapeutic device aimed at treating cancer, life-threatening viral infections, and aiding in organ transplantation. Pre-clinical studies show it can remove harmful exosomes from biological fluids using lectin-based technology. The FDA has designated it as a Breakthrough Device for advanced or metastatic cancer unresponsive to standard therapies and for treating life-threatening viruses not addressed by approved therapies, with an open Investigational Device Exemption. The AEMD YTD return is shown above.
The YTD Return on the AEMD YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AEMD YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AEMD YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|